Evidence map›Paper›PMID 35992328›Full record

ArticleCancer research communications2022

Methylated Septin9 (m

Holli A Loomans-Kropp, Yurong Song, Manish Gala, Aparna R Parikh, Emily E Van Seventer, Rocio Alvarez, Megan P Hitchins, Robert H Shoemaker, Asad Umar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Early Onset Colorectal Cancer: Molecular Underpinnings Accelerating Occurrence.Cellular and molecular gastroenterology and hepatology · 2025
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Holli A Loomans-KroppCancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD 20850.
Yurong SongCancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
Manish GalaGastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Aparna R ParikhDivision of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Emily E Van SeventerDivision of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Rocio AlvarezBiomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048.
Megan P HitchinsBiomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048.
Robert H ShoemakerChemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD 20850.
Asad UmarGastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD 20850.
Massachusetts General Hospital · USCedars-Sinai Medical Center · USPrevention Group · USCenter for Cancer Research · USFrederick National Laboratory for Cancer Research · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI PENDLETON, RICHARD · 2019 to 2025
$3932.6M
Genetics of Sessile Serrated PolypsK23DK103119 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI GALA, MANISH · 2014 to 2018
$960k
Intramural NIH HHS Z99 CA999999NCI NIH HHS 75N91019D00024NIDDK NIH HHS K23 DK103119
6 · The paper itself

Abstract

Early-onset colorectal cancer (EOCRC), defined as a diagnosis under age 50, is an emerging public health burden. As many of these individuals fall outside of screening guidelines, the development of a minimally invasive, accurate screening modality for this population is warranted. We evaluated the FDA-approved blood-based biomarker methylated Septin9 (m

Indexed as

Cell-Free Nucleic AcidsColorectal NeoplasmsBiomarkers, TumorEarly Detection of CancerHumansMiddle AgedSeptinsBiomarkers, TumorCell-Free Nucleic AcidsSeptinsbiomarkerscolorectal cancerearly detectionearly-onsetmethylated Septin9

Identifiers

PMID35992328
PMCPMC9387652
OpenAlexW4210957526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.